Breast Cancer Germline Testing (ASCO) Source: American Society of Clinical Oncology, Society of Surgical Oncology; Medically Reviewed by Dr Fharat Raja

Breast Cancer Germline Testing (ASCO) Germline Testing in Breast Cancer Source: American Society of Clinical Oncology, Society of Surgical Oncology; Medically Reviewed by Dr Fharat Raja In 2024, the American Society of Clinical Oncology (ASCO) and the Society of Surgical Oncology (SSO) published a guideline on germline testing in breast cancer. This Medscape guideline summary covers BRCA1/2 testing for newly diagnosed patients, those with recurrent disease or second primaries, and those with personal history but no active disease, as well as the value of testing for other predisposition genes and genetic counselling. Please refer to the full ASCO–SSO guideline for all recommendations, rationale, and background information. •When to offer BRCA1/2 testing https://reference.medscape.com/cc2/p10/guideline-essentials-asco-sso-recommendations-germline-2025a10004h3?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611 •Testing for stage I–IV disease https://reference.medscape.com/cc2/p10/guideline-essentials-asco-sso-recommendations-germline-2025a10004h3?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611 •Recurrent cancer and PARP inhibitors https://reference.medscape.com/cc2/p10/guideline-essentials-asco-sso-recommendations-germline-2025a10004h3?ecd=WNL_drugguide_251217_MSCPREF_onc_etid7961611&uac=148436CN&impID=7961611